Simris Alg year-end report January-December 2022
Q4, OCTOBER-DECEMBER 2022 · Net revenue decreased by 89% to SEK 318k (2 977k) following a pause in production to upgrade the Hammenhög production facility. · Personnel & other external costs increased by 81% to SEK -5 506k (-3 046k) due to increased investments in capability and including staff Cyano Biotech. · EBITDA declined by 90% to SEK -6 064k (-3 186k). · EBIT/ Operating result declined by 147% to SEK -9 631k (-3 907k). JANUARY - DECEMBER 2022 · Net revenue declined by 34% to SEK 4 080k (6 137k). · Personnel & other external costs decreased by 16,5% to SEK -17